Sanofi (France)

2075 articles about Sanofi (France)

• 

  Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD

  5/22/2023

  Sanofi and Regeneron reported positive results for the anti-inflammatory drug in a chronic obstructive pulmonary disease trial. The companies hope to see approval before a 2024 read-out of a second trial.

• Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

  5/21/2023

  Positive Phase 3 results evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation were shared in the 2023 American Thoracic Society International Conference session “New England Journal of Medicine and JAMA.

• Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine

  5/21/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi presented positive Phase 3 results evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

• EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

  5/19/2023

  Sobi announced that the European Medicines Agency has accepted and validated a marketing authorisation application for efanesoctocog alfa, a new class of high-sustained FVIII developed for the treatment of people with haemophilia A of all age groups.

• 

  Senate Health Committee Seeks to Rein in Drug Prices with Four New Bills

  5/12/2023

  Lawmakers on Thursday voted 18–3 to increase oversight of pharmacy benefit managers and limit their practice of spread pricing, when PBMs charge payers for drugs more than they pay pharmacies.
• 

  Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm

  5/12/2023

  Nirsevimab lowered hospitalizations due to RSV-related lower respiratory tract disease by 83.21%. Friday’s data drop comes ahead of next week’s advisory committee meeting for Pfizer’s RSV hopeful.

• Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

  5/12/2023

  New data from the HARMONIE Phase 3b clinical trial show an 83.21% reduction in hospitalizations due to RSV-related LRTD in infants under 12 months of age who received a single dose of nirsevimab, compared to infants who received no RSV intervention.1.

• 

  Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations

  5/5/2023

  The companies said in first-quarter earnings calls that they want to restructure R&D, cut costs and shift away from high-risk drug development to focus areas.
• 

  Sanofi Deepens Pompe Disease Focus with $150M Maze Partnership

  5/2/2023

  For $150 million upfront, Sanofi will gain access to Maze’s lead asset MZE001, which inhibits the GYS1 protein in the rare genetic disorder.

• Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease

  5/1/2023

  Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications.

• Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

  4/27/2023

  We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses.

• Press Release: Sanofi completes acquisition of Provention Bio, Inc.

  4/27/2023

  Sanofi announced the completion of its acquisition of Provention Bio, Inc. The acquisition adds TZIELD, an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi’s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.

• Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

  4/26/2023

  Sanofi announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Sanofi’s proposed acquisition of Provention Bio, Inc.

• Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

  4/11/2023

  Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus in the United States.

• Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

  4/10/2023

  Sanofi announced that it has withdrawn and refiled its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Sanofi’s pending acquisition of Provention Bio, Inc.

• Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines

  4/4/2023

  Sanofi and the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, celebrated the groundbreaking of a new, state-of-the-art formulation and filling facility at Sanofi's Swiftwater site in Pennsylvania.

• Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

  4/4/2023

  Two studies, published in The Lancet and The Lancet Haematology, evaluating the efficacy and safety of fitusiran, an investigational siRNA therapy for the prophylactic treatment of adults and adolescents with hemophilia A or B, reinforce the potential of this investigational therapy to transform the current standard of care and address unmet needs for all types of hemophilia, regardless of inhibitor status.

• Press Release: Availability of the Q1 2023 Memorandum for modelling purposes

  3/30/2023

  Sanofi announced that its Q1 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website.

• Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 

  3/23/2023

  The primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

• Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial

  3/23/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.